The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Generative AI-powered clinical decision support in germline predisposition to myeloid neoplasms
Carmelo Gurnari, MD, Cleveland Clinic, Cleveland, OH, discusses a generative artificial intelligence (AI)-powered clinical decision support tool designed to help hematologists identify and interpret germline predisposition to myeloid neoplasms. He highlights its potential to guide diagnosis, transplant planning, and clinical decision-making in settings without specialized expertise. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
